Insider Cluster (3 insiders) ·Filed Jul 7, 2026

VRTX

VERTEX PHARMACEUTICALS INC / MA
NEUTRAL
Impact 2/10
Horizonimmediate Processed2mo ago
Insider cluster: 3 insiders, $1.5M total
Actionable Insight • Neutral

The insider sales are too small to carry informational value. Focus on the Crinetics acquisition integration and upcoming earnings for directional cues. Monitor for any larger insider sales post-announcement that could signal skepticism about the deal.

DirectionNeutral
Confidencehigh
Horizonimmediate
Final — all horizons settled through T+60d ⚠ clustered
VRTX ▲ +0.11% at T+60d
NEUTRAL call ✓ call won +0.11% · α vs SPY -1.89% · entry $522.25 → $522.81
Entry anchored
Jul 6, 03:59 PM ET
via exchange tick
T+1d
-4.56%
call -4.56% · α -4.25%
$498.43
settled 3mo ago
T+5d
-8.80%
call -8.80% · α -9.35%
$476.31
settled 3mo ago
T+20d
-9.87%
call -9.87% · α -11.20%
$470.72
settled 2mo ago
T+60d
+0.11%
call +0.11% · α -1.89%
$522.81
settled 3d ago

Price Chart

Loading chart...

Executive Summary

Three Vertex EVPs sold a total of $1.49M in stock over a one-week period ending July 2, 2026, representing less than 0.001% of the company's $134.4B market cap. The sales occurred just before Vertex announced a $10B acquisition of Crinetics Pharmaceuticals on July 7, but the dollar amounts are immaterial and likely reflect routine portfolio management or pre-planned 10b5-1 transactions.

Key Financial Metrics

Direction
selling
Total Value
$1.5M
Insiders
3

Key Facts

  • Three EVPs (Chief Regulatory & Quality Officer, CMO, Chief Legal Officer) sold shares between June 25 and July 2, 2026.
  • Total sales value: $1.49M, or ~0.0011% of Vertex's $134.4B market cap.
  • Sales occurred before the July 7 announcement of a $10B acquisition of Crinetics Pharmaceuticals.
  • All transactions were open-market sales (code S).
  • Non-cash transactions (grants, exercises, tax withholdings) were absent from the cluster.

Financial Impact

Trivial — $1.49M in insider sales is immaterial relative to $134.4B market cap.

Risk Factors

  • None material from this cluster; the acquisition integration risk is the primary concern.

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
83% bullish (40 analysts)

Investment Themes

Biotech & Drug Discovery

Documents Analyzed

This report is based on 1 SEC document filed with EDGAR.

DocumentAccession Number
CLUSTER Data (Synthetic)cluster-VRTX-1783491146467
11 reports for VRTX
Performance horizon

Track record builds as more directional reports settle.

Filters
Rows
Reports for VRTX — sortable, filterable
TypeNow
Jul 7, 2026
12w ago
8-K
BULLISH ★ 7/10
$522.25 $522.81▲ +0.11%▼ −1.89%$506.74 (−2.97%)
Jul 7, 2026
12w ago
Insider Cluster
NEUTRAL ★ 2/10
$522.25 $522.81▲ +0.11%▼ −1.89%$506.74 (−2.97%)
Jul 6, 2026
12w ago
Insider Cluster
NEUTRAL ★ 2/10
$529.59 $526.73▼ −0.54%▼ −2.26%$506.74 (−4.31%)
Jun 3, 2026
17w ago
Insider Cluster
NEUTRAL ★ 2/10
$441.47 $541.69▲ +22.70%▲ +21.08%$506.74 (+14.79%)
May 19, 2026
19w ago
Insider Cluster
NEUTRAL ★ 2/10
$430.05 $505.75▲ +17.60%▲ +12.87%$506.74 (+17.83%)
Mar 11, 2026
29w ago
Insider Cluster
NEUTRAL ★ 3/10
$491.96 $428.34▼ −12.93%▼ −24.45%$506.74 (+3.01%)
Feb 25, 2026
31w ago
Insider Cluster
NEUTRAL ★ 4/10
$482.92 $430.44▼ −10.87%▼ −17.82%$506.74 (+4.93%)
Feb 25, 2026
31w ago
Insider Cluster
BEARISH ★ 6/10
$482.92 $430.44▲ +10.87%▲ +17.82%$506.74 (−4.93%)
Feb 25, 2026
31w ago
Insider Cluster
NEUTRAL ★ 3/10
$482.92 $430.44▼ −10.87%▼ −17.82%$506.74 (+4.93%)
Feb 25, 2026
31w ago
Insider Cluster
NEUTRAL ★ 4/10
$482.92 $430.44▼ −10.87%▼ −17.82%$506.74 (+4.93%)
Showing 10 of 11

US Market Status

Market Closed — Opens in 1h 20m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access
Report published Jul 8, 2026